Mutabilis is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support. We currently have alliances with or receive funding support from the following:
ENABLE for EBL-1463 program
In 2017 Mutabilis DABOCIN program was granted the ENABLE support (http://nd4bb-enable.eu/). ENABLE program belongs to the New Drugs For Bad Bugs (ND4BB) action (http://www.nd4bb.eu/) and supports / accelerates the development of novel antibiotics targeting the most worrisome Gram-negative pathogens. ND4BB is funded by IMI (Innovative Medicine Initiative), the largest Publi-Private Partnership in the field of Life Sciences (http://www.imi.europa.eu/). Through this platform Mutabilis has access to a whole range of services supporting its Dabocins program.
Novo Holdings REPAIR Impact fund for 2G-Dabocin program
In January 2020, Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis. This investment will allow the company to accelerate this 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.